Who Paid My Doc
Nicholas Petruzzi
Vascular & Interventional Radiology Galloway, NJ Medical Doctor
NPI 1932360658 CMS profile 133607
44 E Jimmie Leeds Rd, Galloway, NJ 08205
General payments
$406,708
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$98,192
Through program year 2025, Nicholas Petruzzi of Galloway, NJ is reported in the CMS Open Payments database as having received $406,708 across 589 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $98,192 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 98th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $104,167 | 137 | |
| 2024 | General | $74,170 | 98 | |
| 2023 | General | $68,635 | 110 | |
| 2022 | General | $64,402 | 82 | |
| 2021 | General | $37,742 | 59 | |
| 2020 | General | $25,696 | 34 | |
| 2019 | General | $31,897 | 69 |
Beside peers
- Nicholas Petruzzi
- Vascular & Interventional Radiology median
- Middle half of Vascular & Interventional Radiology
- National median
In program year 2025, general payments to Nicholas Petruzzi were reported at $104,167. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.
Show as a table
| Year | Nicholas Petruzzi | Vascular & Interventional Radiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $31,897 | $422 | $125–$1,555 | $163 |
| 2020 | $25,696 | $200 | $68–$652 | $114 |
| 2021 | $37,742 | $280 | $99–$866 | $132 |
| 2022 | $64,402 | $433 | $137–$1,497 | $149 |
| 2023 | $68,635 | $506 | $152–$2,019 | $160 |
| 2024 | $74,170 | $556 | $175–$1,930 | $164 |
| 2025 | $104,167 | $534 | $166–$2,075 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 161 billing codesPaid by Medicare
$783,486
Medicare patients
337
Services billed
15,427
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 55% | |
| Ischemic heart disease | 53% | |
| Diabetes | 52% | |
| Chronic kidney disease | 47% | |
| Heart failure | 39% | |
| Atrial fibrillation | 37% | |
| COPD | 32% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 69 | 12,662 | $1,316 |
| Injection, cefazolin sodium, 500 mg J0690 | Office | 46 | 254 | $157 |
| Injection, hydromorphone, up to 4 mg J1170 | Office | 13 | 13 | $36 |
| Injection, diphenhydramine hcl, up to 50 mg J1200 | Office | 21 | 26 | $16 |
| Injection, fentanyl citrate, 0.1 mg J3010 | Office | 15 | 21 | $15 |
| Injection, ondansetron hydrochloride, per 1 mg J2405 | Office | 26 | 132 | $9 |
| Injection, midazolam hydrochloride, per 1 mg J2250 | Office | 23 | 74 | $7 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Nayzilam |
|
$125 | — | — |
| RINVOQ |
|
$21 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
589 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Vascular & Interventional Radiology in New Jersey
John Rundback
Vascular & Interventional Radiology · Teaneck, NJ
Sabina Amin
Vascular & Interventional Radiology · Camden, NJ
Israel Schur
Vascular & Interventional Radiology · Clifton, NJ
Micah Watts
Vascular & Interventional Radiology · Galloway, NJ
Kevin Herman
Vascular & Interventional Radiology · Teaneck, NJ
Elsie Koh
Vascular & Interventional Radiology · Woodland Park, NJ
Related records
Vascular & Interventional Radiology in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Vascular & Interventional Radiology
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.